[ET Net News Agency, 10 June 2025] J.P. Morgan raised the target price for Innovent Bio 
(01801) to HKD84 from HKD74 and maintained the "overweight" rating. 
  The research house said after IBI363's better-than-expected OS data at ASCO '25 boosted 
Innovent's share price, it expects ongoing clinical catalysts to further drive  
performance. (rc)